First-Line Treatment for Chronic Bacterial Prostatitis
Chronic bacterial prostatitis (CBP) is a persistent bacterial infection of the prostate. This protocol addresses empirical first-line antimicrobial management, structured around a specific class of antibiotics selected for its favourable pharmacokinetic properties and antibacterial activity against the relevant uropathogens.
Treatment approach
First-line management centres on an oral fluoroquinolone antibiotic, chosen for its favourable pharmacokinetic properties, generally good safety profile, and antibacterial activity against Gram-negative pathogens. The specific agent, optimal dosing regimen, and required course length are set out in the full structured protocol.
Treatment goal
The primary clinical endpoint is:
Cessation of prostatitis symptoms
References
- Fluoroquinolones, despite the high resistance rates of uropathogens, are recommended as first-line agents in the empirical treatment of CBP, due to their favourable pharmacokinetic properties, their generally good safety profile, and antibacterial activity against Gram-negative pathogens, including P. aeruginosa and C. trachomatis.
- Prescribe a fluoroquinolone (e.g. ciprofloxacin, levofloxacin) as first-line treatment for CBP.
- In CBP, antimicrobials should be given for four to six weeks after initial diagnosis.
- In asymptomatic post-treatment patients, routine urinalysis and/or urine culture is not mandatory as there are no validated tests of cure for bacterial prostatitis except for cessation of symptoms.
View source ↗